Cilostazol

Cilostazol is an orally active drug that acts as a selective inhibitor of phosphodiesterase type 3 and behaves as both an antiplatelet agent and a vasodilator. It was introduced to treat the symptoms of reduced blood flow in the legs, and it belongs to the same broad enzyme-inhibitor family as several heart-failure drugs, a relationship that shapes its safety profile.

The medicine was approved by the United States Food and Drug Administration in 1999 and is now available as a low-cost generic in oral tablet form. Beyond its main indication, it is used in parts of Asia for secondary prevention after stroke and to reduce re-narrowing of arteries after stent placement, uses that fall outside its original labeling in many countries.

The best-established use is intermittent claudication, the cramping leg pain that appears on walking in peripheral artery disease. In double-blind randomized trials, patients taking cilostazol walked significantly farther before the onset of pain and before reaching maximal distance than those on placebo, and a meta-analysis pooling six controlled trials found consistent improvements in treadmill walking distance and in questionnaire measures of physical function and quality of life ^[2]. A Cochrane systematic review reached a similar conclusion, confirming that cilostazol improves walking distance in stable claudication, while noting that it has not been shown to reduce cardiovascular events or death ^[3]. Reviews also describe its blend of platelet inhibition and direct vasodilation and its advantage over pentoxifylline and placebo in early trials ^[1].

The most important safety limitation is that cilostazol is contraindicated in heart failure of any severity, because other oral drugs that inhibit phosphodiesterase 3 have increased mortality in patients with that condition. The most common side effects are headache, diarrhea, dizziness, and palpitations, which reflect its vasodilating action ^[1].

Cilostazol is prescription only and carries a boxed warning: it is contraindicated in heart failure of any severity, because other PDE3 inhibitors raised mortality in heart failure patients. The most common effects are headache, which can be significant, along with diarrhea, loose stools, dizziness, and palpitations from its heart-rate-raising, vasodilating action. Because it affects platelets it can increase bleeding risk, so it is used carefully alongside other blood thinners. Its levels rise with strong inhibitors of the CYP3A4 and CYP2C19 enzymes and with grapefruit juice, which calls for a reduced dose. Benefits build over weeks, so it is not an on-the-spot pain reliever, and it is stopped if there is no improvement after about three months.

Cilostazol is a phosphodiesterase 3 inhibitor cleared by CYP3A4 and CYP2C19, and both routes generate clinically relevant interactions. Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, erythromycin, clarithromycin and diltiazem raise cilostazol exposure and amplify its dose-related effects: headache, palpitations, tachycardia. Grapefruit juice does the same thing at the intestinal level. CYP2C19 inhibitors, omeprazole most commonly, raise concentrations of the active dehydro metabolite, which carries several times the antiplatelet potency of the parent compound.

CYP3A4 inducers such as rifampin and carbamazepine reduce exposure and can blunt the walking-distance benefit in claudication.

Because cilostazol inhibits platelet aggregation in its own right, adding aspirin, clopidogrel or an anticoagulant increases bleeding risk; the combination is common in practice, but the additive effect is real. Its vasodilator and chronotropic effects can also compound those of other vasodilators and rate-raising drugs.

Checking a whole stack? Run it through interactions + stacks.

Cilostazol was discovered and developed by the Japanese company Otsuka Pharmaceutical, emerging in the 1980s from research into selective inhibitors of phosphodiesterase type 3, the enzyme that regulates intracellular cyclic AMP. By raising cyclic AMP in platelets and vascular smooth muscle it produced a dual antiplatelet and vasodilator effect, a combination well suited to improving blood flow in the limbs.

It was approved in the United States in 1999 under the brand name Pletal for the treatment of intermittent claudication, the exercise-induced leg pain of peripheral artery disease. Its development history was shaped by an important class effect: because other phosphodiesterase 3 inhibitors had increased mortality in patients with heart failure, cilostazol carries a firm warning against use in that setting. It has since become available as a generic and remains a specific tool for the symptomatic relief of claudication.

Cilostazol holds a well-defined and respected niche as one of the few medications shown in controlled trials to lengthen the distance patients with intermittent claudication can walk before pain sets in. Systematic reviews, including a Cochrane analysis of thousands of participants, confirm a consistent improvement in both initial and absolute claudication distance versus placebo, with possible gains in quality of life, distinguishing it from many treatments that failed to demonstrate benefit.

Vascular specialists appreciate its combined antiplatelet and vasodilator action and its role as a symptomatic therapy that can meaningfully improve daily function. Balanced against this, headache is a notably common side effect, and the drug is strictly contraindicated in heart failure, a caution that firmly bounds its use. Evidence on harder outcomes such as amputation and cardiovascular events remains limited, so it is valued specifically for symptom relief rather than for altering disease course.